Thursday 16 October, 2025
Objectives: Chronic kidney disease (CKD) is a major public healthcare priority. Patients with CKD are also at higher risk of comorbidities…
Read moreAbstracts
Pharmacometric analysis to justify a higher recommended dose for trastuzumab deruxtecan in the treatment of subjects with metastatic gastric cancer versus breast cancer
Thursday 16 October, 2025
Introduction: Trastuzumab deruxtecan (T-DXd) is a newer antibody-drug conjugate consisting of an anti-HER2 antibody linked to a topoisomerase I inhibitor….
Read moreImproving the tolerability of osimertinib by identifying its toxic limit
Thursday 16 October, 2025
Objectives: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). Nonetheless,…
Read moreDevelopment of covariate-informed model pooling method to predict the correct starting dose
Thursday 16 October, 2025
Objectives: An increasing number of population pharmacokinetic (POP-PK) models have been developed which can predict plasma concentrations based solely on…
Read moreA QSP model characterizing valproic acid -induced hyperammonemia and the impact of carnitine supplementation
Thursday 16 October, 2025
Introduction: Valproic acid (VPA) is a narrow therapeutic index drug widely prescribed for the treatment of epilepsy, psychiatric disorders and…
Read moreImplementation of non-linear mixed effects models in NONMEM described by fractional differential equations.
Thursday 16 October, 2025
Introduction: Fractional calculus has been used within the last couple of decades, to describe anomalous diffusion (i.e. diffusion not described…
Read moreIn Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data
Thursday 16 October, 2025
Introduction: The aim of this work is to develop a Physiologically Based Pharmacokinetic model (PBPK) for the radiopharmaceutical Tc99m-Tetrofosmin in humans,…
Read moreQuantification of model misspecification of population pharmacokinetic models by a machine learning postprocessing correction of the residual variability
Thursday 16 October, 2025
Objectives: In Population Pharmacokinetics (PopPK) residual unexplained variability (RUV) characterizes the remaining observed variability having taken into account the variability…
Read moreExternal evaluation of published population pharmacokinetic models of adalimumab in inflammatory bowel disease patients
Thursday 16 October, 2025
Introduction: Adalimumab is a fully human monoclonal antibody that belongs to the group of tumor necrosis factor (TNF)-alpha inhibitors. It…
Read moreModelling fatigue events in prostate cancer patients on radiotherapy
Thursday 16 October, 2025
Introduction: The second most common form of cancer in the male population is prostate cancer. Therapeutic options include radical prostatectomy, different…
Read more